The EDEM2 Knockout K-562 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the EDEM2 gene has been disrupted to abolish its expression. This polyclonal knockout model is derived from the K-562 cell line and serves as a loss-of-function tool for investigating EDEM2-mediated glycoprotein endoplasmic reticulum-associated degradation (ERAD). The heterogeneous knockout population retains the oncogenic background of the parental cells while lacking functional EDEM2, enabling robust phenotypic analyses in a leukemia context.
The parental K-562 cell line is a well-characterized chronic myelogenous leukemia (CML) lymphoblast cell line originally isolated from the pleural effusion of a 53-year-old female patient in blast crisis. K-562 cells harbor the BCR-ABL fusion oncogene, which drives constitutive tyrosine kinase activity and aberrant cell proliferation, and are widely used to study BCR-ABL-driven leukemogenesis, drug resistance mechanisms, and hematopoietic differentiation pathways.
EDEM2 encodes an ER-resident mannosidase-like lectin that plays a central role in ERAD by trimming terminal mannose residues from misfolded glycoproteins, thereby facilitating their recognition by the ERAD lectins OS9 and XTP3-B. This event promotes substrate retrotranslocation through the SEL1L-HRD1 complex, extraction by the p97/VCP ATPase, and subsequent ubiquitination and proteasomal degradation. EDEM2 expression is upregulated by ER stress through the transcription factors XBP1s and ATF6, positioning it as a key component of the unfolded protein response (UPR).
In K-562 cells, BCR-ABL signaling is known to impose proteostatic stress, leading to chronic activation of the UPR and ERAD pathways. Disruption of EDEM2 in this leukemic background likely impairs the clearance of misfolded glycoproteins, sensitizing cells to ER stress and potentially altering BCR-ABL-driven survival signaling. Consequently, this polyclonal knockout model provides a unique system to dissect the contribution of EDEM2-dependent ERAD to leukemia cell homeostasis and drug resistance, and to explore synthetic lethal interactions with proteasome inhibitors or ER stress inducers.
Typical applications include analyzing ERAD substrate turnover using reporter substrates such as CD3??-YFP, assessing sensitivity to ER-stressing agents (tunicamycin, thapsigargin) via flow cytometric viability assays, and examining UPR activation by western blotting for GRP78 and CHOP or RT-qPCR for XBP1s splicing. Co-immunoprecipitation experiments with SEL1L can probe altered ERAD complex assembly. This polyclonal knockout population is ideally suited for high-throughput screens to identify ERAD modulators or to test combination therapies targeting proteostasis in CML. For additional information, please contact Ascent Research.
